Akari therapeutics,  a clinical-stage biopharmaceutical company based in the US, has announced that it will be advancing a program for the inhaled delivery of nomacopan for lung diseases. The company said that it will be working with Inhalation Sciences to refine dosing and pharmacokinetics of nomacopan for both dry powder and nebulized delivery. The company said that the decision was taken amid resounding research data that nomacopan, a potent inhibitor of both C5 and LTB4, can be a focused therapy for disease exacerbations across multiple severe lung disorders, including severe asthma, COPD and Covid. In addition, the company’s observational studies on COPD and Covid-19 pneumonia indicated that elevated levels of complement C5 and LTB4 and the severity of exacerbations in COPD patients was associated with the initial levels of C5.